Têtu, B <br/><br/>
p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.  [electronic resource] 

 -  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc  Sep 1998 
 - 823-30 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0893-3952 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--metabolism<br/>Chemotherapy, Adjuvant<br/>Combined Modality Therapy<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Middle Aged<br/>Prognosis<br/>Proportional Hazards Models<br/>Receptor, ErbB-2--metabolism<br/>Retrospective Studies<br/>Survival Rate<br/>Tumor Suppressor Protein p53--metabolism